trending Market Intelligence /marketintelligence/en/news-insights/trending/yc7vjlai5bjwbunl-o2oaq2 content esgSubNav
In This List

Protalix BioTherapeutics appoints independent director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Protalix BioTherapeutics appoints independent director

Protalix BioTherapeutics Inc. appointed David Granot to its board as an independent director.

Granot brings his financial and banking knowledge to the company. He was the CEO of First International Bank of Israel Ltd. from 2001 to 2007. He also served as the CEO of the Israel Discount Bank Ltd. from 1998 to 2000.

Israel-based Protalix BioTherapeutics is a biotechnology company engaged in the development and commercialization of recombinant therapeutic proteins using ProCellEx, its proprietary plant cell-based expression system.